LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
79.75
+0.03 (+0.04%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close79.72
Open78.96
Bid77.92 x 100
Ask81.32 x 100
Day's Range78.55 - 79.75
52 Week Range73.69 - 89.09
Volume4,989,439
Avg. Volume4,992,043
Market Cap83.103B
Beta0.24
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.25 (2.82%)
Ex-Dividend Date2018-02-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • MarketWatch17 hours ago

    Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug

    Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...

  • MarketWatch22 hours ago

    Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug

    Eli Lilly & Co. shares fell 1.8% premarket and Incyte Corp. shares dropped 4.5% premarket on Thursday after a Food and Drug Administration briefing document raised issues with their rheumatoid arthritis drug baricitinib. The drug will go up before a FDA arthritis advisory committee meeting on Monday. The FDA often follows an advisory committee's recommendation, though there are exceptions.

  • Novartis’s Innovative Medicines Segment in 1Q18
    Market Realist3 days ago

    Novartis’s Innovative Medicines Segment in 1Q18

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.

  • 5 Drug Stocks Poised to Surpass on Earnings This Quarter
    Zacks3 days ago

    5 Drug Stocks Poised to Surpass on Earnings This Quarter

    The outlook for the upcoming first-quarter results looks bright.

  • Celldex's Phase II Breast Cancer Study Fails, Shares Plunge
    Zacks3 days ago

    Celldex's Phase II Breast Cancer Study Fails, Shares Plunge

    Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.

  • Expectations from Novartis’s 1Q18 Earnings
    Market Realist3 days ago

    Expectations from Novartis’s 1Q18 Earnings

    Headquartered in Basel, Switzerland, Novartis (NVS) is one of the largest pharmaceutical companies by revenue. Novartis specializes in the development, manufacturing, and marketing of healthcare products.

  • Risankizumab Could Be AbbVie’s Long-Term Growth Driver
    Market Realist3 days ago

    Risankizumab Could Be AbbVie’s Long-Term Growth Driver

    In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.

  • Merck's Keytruda Reduces Death Risk in Melanoma Patients
    Zacks4 days ago

    Merck's Keytruda Reduces Death Risk in Melanoma Patients

    Merck's (MRK) Keytruda significantly prolongs RFS and reduces the risk of disease recurrence or death by 43% versus placebo in a phase III study in high-risk stage III melanoma patients.

  • Better Buy: Eli Lilly and Company vs. Johnson & Johnson
    Motley Fool5 days ago

    Better Buy: Eli Lilly and Company vs. Johnson & Johnson

    J&J has been the bigger winner in the past, but could Lilly's pipeline give it an advantage now?

  • MarketWatch7 days ago

    Eli Lilly's stock rallies after BMO raises rating, price target

    Shares of Eli Lilly & Co. rallied 1.2% in morning trade Friday, after BMO Capital backed away from its bearish stance that it's kept for the past year, given the belief that previous concerns are now mostly ...

  • Better Buy: AbbVie Inc. vs. Eli Lilly
    Motley Fool7 days ago

    Better Buy: AbbVie Inc. vs. Eli Lilly

    How the giant drugmakers compare when it comes to growth, dividends, and valuation.

  • Olumiant Could Boost Incyte’s Revenues
    Market Realist8 days ago

    Olumiant Could Boost Incyte’s Revenues

    In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis (or RA) and who did not respond sufficiently or could not tolerate disease-modifying antirheumatic drugs (or DMARDs). In July 2017, the drug was approved by the Japan Ministry of Health, Labor, and Welfare for RA patients who don’t respond sufficiently to standard-of-care treatment options. The drug is also approved in Switzerland for the RA indication.

  • Incyte Has Diversified Its Revenues across Multiple Product Lines
    Market Realist8 days ago

    Incyte Has Diversified Its Revenues across Multiple Product Lines

    Incyte (INCY) expects to report GAAP (generally accepted accounting principles) and non-GAAP revenues in the range of $80 million to $85 million from the sale of Iclusig in fiscal 2018. In June 2016, Incyte entered a licensing agreement with Ariad Pharmaceuticals for the development and commercialization of kinase inhibitor, Iclusig, in the European Union and 22 other countries.

  • Novartis’s Valuation and Analysts’ Recommendations on April 11
    Market Realist9 days ago

    Novartis’s Valuation and Analysts’ Recommendations on April 11

    Novartis AG (NVS) reported EPS (earnings per share) of $1.21 on revenue of ~$12.9 billion in 4Q17, a 5% rise compared to $12.3 billion in 4Q16. Novartis is expected to report revenue of $12.5 billion in 1Q18 compared to $11.5 billion in 1Q17. On April 11, 2018, Novartis was trading at a forward PE of ~14.9x.

  • Incyte Expected to Report Robust Revenue Growth in Fiscal 2018
    Market Realist9 days ago

    Incyte Expected to Report Robust Revenue Growth in Fiscal 2018

    In 2017, Incyte (INCY) reported total revenues of close to $1.5 billion, which was year-over-year (or YoY) growth of around 38.9%. The company earned revenues close to $1.1 billion from the sale of Jakafi, a JAK1/JAK2 inhibitor, in the US, and $152 million as royalties received from Novartis (NVS) on the sale of Jakafi, marketed as Jakavi, in international markets. Wall Street analysts have projected Incyte’s fiscal 2018 revenues to be close to $1.8 billion, which is a YoY rise of around 16.9%.

  • Is Beaten-Down Incyte Corporation Stock a Buy Now?
    Motley Fool9 days ago

    Is Beaten-Down Incyte Corporation Stock a Buy Now?

    A clinical-trial flop with epacadostat isn't the end of the world for Incyte.

  • A Look at Eli Lilly’s 1Q18 Stock Performance
    Market Realist9 days ago

    A Look at Eli Lilly’s 1Q18 Stock Performance

    Eli Lilly and Company (LLY) is a US pharmaceutical company with headquarters in Indianapolis, Indiana. The company specializes in products for both human health and animal health.

  • AbbVie's RA Candidate Meets Primary Endpoints in Phase III
    Zacks10 days ago

    AbbVie's RA Candidate Meets Primary Endpoints in Phase III

    AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.

  • Top Ranked Growth Stocks to Buy for April 10th
    Zacks10 days ago

    Top Ranked Growth Stocks to Buy for April 10th

    Top Ranked Growth Stocks to Buy for April 10th

  • How Bristol-Myers Squibb Stock Performed in 1Q18
    Market Realist10 days ago

    How Bristol-Myers Squibb Stock Performed in 1Q18

    Bristol-Myers Squibb (BMY) is an American pharmaceutical company with headquarters in New York City. Bristol-Myers Squibb specializes in cardiovascular products, immunoscience products, neuroscience products, oncology products, and virology products.

  • Better Buy: Eli Lilly and Co. vs. GlaxoSmithKline
    Motley Fool13 days ago

    Better Buy: Eli Lilly and Co. vs. GlaxoSmithKline

    Both of these pharmaceutical giants are trading at cheap valuations and offer big dividends, due to troubles that are mostly behind them.

  • Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus
    Zacks14 days ago

    Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus

    Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study

  • Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study
    Zacks15 days ago

    Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study

    A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.

  • FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus
    Zacks15 days ago

    FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus

    The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.

  • Why Exelixis Will Triumph In Liver Cancer Battle With Eli Lilly
    Investor's Business Daily16 days ago

    Why Exelixis Will Triumph In Liver Cancer Battle With Eli Lilly

    A battle brewing in liver cancer will land Exelixis on top, an analyst said Wednesday after rival Eli Lilly posted strong topline results for its drug.